Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: Therapeutic implications through protein modeling

Clinical Cancer Research

Volumn 11, Issue 10, 2005, Pages 3668-3677

  Tarn, Chi ^a   Merkel, Erin ^a   Canutescu, Adrian A ^a   Shen, Wei ^a   Skorobogatko, Yuliya ^a   Heslin, Martin J ^b   Eisenberg, Burton ^c   Birbe, Ruth ^a   Patchefsky, Arthur ^a   Dunbrack, Roland ^a   Arnoletti, J Pablo ^b   Von Mehren, Margaret ^a   Godwin, Andrew K ^a,d  

^a Fox Cancer Center   (United States)

^b Kentucky   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVATION; EXON; FAMILIAL CANCER; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE ACTIVATION; GENE MUTATION; HUMAN; KIT ONCOGENE; MALE; MOLECULAR MODEL; ONCOGENE; PRIORITY JOURNAL;

ADULT; AGED; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CRYSTALLOGRAPHY, X-RAY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; PEDIGREE; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 21044451716     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2515     Document Type: Article

References (63)

1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-19.
2. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I. Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999;23:377-89.
3. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
4. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-34.
5. Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986;320:415-21.
6. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human protooncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-51.
7. Claesson-Welsh L, Eriksson A, Westermark B, Heldin CH. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. Proc Natl Acad Sci U S A 1989;86:4917-21.
8. Yarden Y, Escobedo JA, Kuang WJ, et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986;323:226-32.
9. Coussens L, Van Beveren C, Smith D, et al. Structural alteration of viral homologue of receptor protooncogene fms at carboxyl terminus. Nature 1986;320:277-80.
10. Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993;82:1110-9.
11. Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A 1994;91:459-63.
12. Broudy VC. Stem cell factor and hematopoiesis. Blood 1997;90:1345-64.
13. Rousset D, Agnes F, Lachaume P, Andre C, Galibert F. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin-like domains. J Mol Evol 1995;41:421-9.
14. Ishikawa K, Komuro T, Hirota S, Kitamura Y. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats. Cell Tissue Res 1997;289:137-43.
15. Russell ES. Hereditary anemias of the mouse: a review for geneticists. Adv Genet 1979;20:357-459.
16. Nocka K, Majumder S, Chabot B, et al. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes Dev 1989;3:816-26.
17. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A. Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 1992;52:713-7.
18. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC. Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992;80:374-81.
19. Migliaccio G, Migliaccio AR, Valinsky J, et al. Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells. Proc Natl Acad Sci U S A 1991;88:7420-4.
20. Dolci S, Williams DE, Ernst MK, et al. Requirement for mast cell growth factor for primordial germ cell survival in culture. Nature 1991;352:809-11.
21. Tsai M, Shih LS, Newlands GF, et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J Exp Med 1991;174:125-31.
22. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995;373:347-9.
23. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
24. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-94.
25. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
26. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-45.
27. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002;21:8541-6.
28. Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002;8:S14-8.
29. von Mehren M, Blanke CD, Joensuu H, et al. High incidence of durable responses induced by Imatinib Mesylate (GleevecTM) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs). In: The American Society of Clinical Oncology, editors. Orlando (FL); 2002. p. a1608.
30. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
31. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-95.
32. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-63.
33. Canutescu AA, Shelenkov AA, Dunbrack RL Jr. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci 2003;12:2001-14.
34. Huang CC, Couch GS, Pettersen EF, Ferrin TE. Chimera: an extensible molecular modeling application constructed using standard components. In: Pacific Symposium on Biocomputing. 1996. p. 724.
35. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002;10:81-9.
36. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-25.
37. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091-5.
38. Kinoshita K, Isozaki K, Hirota S, et al. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003;18:147-51.
39. Kim TW, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004;10:3076-81.
40. Hou YY, Tan YS, Sun MH, et al. C-kit gene mutation in human gastrointestinal stromal tumors. World J Gastroenterol 2004;10:1310-4.
41. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 2002;38 Suppl 5:S52-9.
42. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
43. Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother 2003;4:869-74.
44. Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Huntingt) 2003;17:1615-20; discussion 20, 23, 26 passim.
45. von Mehren M. Recent advances in the management of gastrointestinal stromal tumors. Curr Oncol Rep 2003;5:288-94.
46. von Mehren M. Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy. Cancer Invest 2003;21:553-63.
47. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
48. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-95.
49. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
50. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
51. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213-20.
52. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998;19:323-4.
53. Maeyama H, Hidaka E, Ota H, et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001;120:210-5.
54. Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157:1581-5.
55. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002;122:1493-9.
56. Robson ME, Glogowski E, Sommer G, et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res 2004;10:1250-4.
57. Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 2003;23:3067-78.
58. Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ. Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999;274:13399-402.
59. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J Invest Dermatol 1999;112:165-70.
60. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
61. Broderick DK, Di C, Parrett TJ, et al. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004;64:5048-50.
62. Bachman KE, Argani P, Samuels Y, et al.The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772-5.
63. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.